DR. ANJALIKA PARHI

DR. SANTOSH MAHAPATRA, DR.GAYATRI KANUNGO, DR.ANUJA MOHANTY, DR. PALLAVI SHREE

Abstract

A hospital based prospective and comparative study of treatment naïve DME patients was conducted between Jan 2019 and February 2021 with a minimum F/U period of 6 months, where 30 patients received one dose of Intravitreal Dexamethasone implant (Gr1) and other group (Gr2) of 30 received 3 consecutive monthly doses of Ranibizumab . Presenting vision, age, gender, duration of diabetes, Intraocular pressure, FFA, OCT, blood sugar levels were noted. The mean decrease in CMT in Gr1 was 213.01µ after 3 months and 230.21µ after 6months. Mean increase in visual acuity as seen by LogMAR chart was 0.445 , Mean increase in IOP 0.734 at the end of 6 months follow-up. In Gr2 the mean decrease in CMT was 205.37µ after 3 months and 210.79µ after 6months. Mean increase in visual acuity was 0.47, mean decrease in IOP was 0.86 at the end of 6 months follow-up. Hence, intravitreal Dexamethasone is non inferior to Ranibizumab in treatment naive DME and the outcome was comparable at 6 months follow up.